If you've been exploring treatment options for PMDD, this review brings together the latest evidence on how hormonal therapies — not just antidepressants — may help. It covers a wide range of approaches and explains why they might work for some people.
A key takeaway is that PMDD isn't caused by abnormal hormone levels. Instead, research suggests that people with PMDD have a heightened brain sensitivity to the normal rise and fall of hormones like estrogen and progesterone during the menstrual cycle. Genetic differences (in something called the ESC/E(Z) gene network, found in over half of women with PMDD) may partly explain this sensitivity. This understanding is important because it validates that PMDD is a real biological condition — not "just hormones."
The review discusses several hormonal treatment options. Certain birth control pills, especially those containing drospirenone (like Yasmin) or nomegestrol acetate with estradiol (Zoely), have shown benefits for PMDD mood symptoms in studies. A pilot study found that nearly 75% of women taking Zoely reported improved mood. For more severe cases, GnRH drugs that temporarily pause the menstrual cycle can be effective, with response rates up to 75%, though they're typically limited to six months due to side effects. Newer options like ulipristal acetate and drugs targeting allopregnanolone (a progesterone byproduct that affects brain chemistry) are being researched and show early promise.
The authors emphasize that treatment should be personalized — what works for one person may not work for another. They also note that while SSRIs remain a common first-line treatment, they don't address the underlying hormonal sensitivity driving PMDD. If you're interested in discussing hormonal treatment options, this review could be a helpful conversation starter with your healthcare provider.
Key findings
- PMDD affects an estimated 3.2% of women of reproductive age using strict diagnostic criteria, though prevalence is likely higher with broader definitions
- The ESC/E(Z) gene network is altered in over 50% of women with PMDD, potentially increasing sensitivity to gonadal hormone fluctuations
- Women with PMDD show no significant differences in standard gonadal hormone levels compared to unaffected women, suggesting heightened central nervous system sensitivity rather than abnormal hormone levels
- A pilot study of nomegestrol acetate/17β-estradiol (Zoely) for PMDD found 74.5% of women reported a positive mood response with significant reductions in depression, anxiety, and stress scores
- GnRH analogues for severe PMDD achieve response rates up to 75% compared to placebo but are limited to 6 months of use due to estrogen deficiency side effects
- Ulipristal acetate (5 mg daily) showed significant symptom improvement over 3 months compared to placebo in a proof-of-concept RCT of 95 women with PMDD
Methods, briefly
Narrative review synthesizing findings from clinical trials, meta-analyses, Cochrane reviews, and observational studies on hormonal treatments for PMDD, postnatal depression, and menopausal depression. No original data collection; no systematic search methodology described.
Limitations to keep in mind
- Narrative review without systematic search methodology, increasing risk of selection bias in cited studies
- Many of the cited studies for PMDD hormone treatments are small or of low quality, as acknowledged by the authors
- The review does not provide a formal quality assessment of included evidence
- One of the authors is an editorial board member of the publishing journal
- Several promising treatments discussed (e.g., sepranolone, dutasteride for PMDD) have very limited evidence or are no longer in production
The latest PMDD research, in your pocket
The app’s research feed is updated daily with newly published, peer-reviewed PMDD work - summarized in plain language.